2024
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Amini A, Zaha V, Hamad E, Woodard P, Rimner A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Higgins K, Iyengar P, Juloori A, Movsas B, Ning M, Park H, Rodrigues G, Wolf A, Simone C. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. Journal Of Thoracic Oncology 2024, 19: 1654-1667. PMID: 39313150, PMCID: PMC11665043, DOI: 10.1016/j.jtho.2024.09.1433.Peer-Reviewed Original ResearchConceptsCardiac toxicityCardiac comorbiditiesThoracic radiotherapyToxicity preventionAmerican Radium Society Appropriate Use CriteriaAbsence of cardiovascular risk factorsLow riskHigh riskMultidisciplinary consensus guidelinesTreatment-related risksAppropriate Use CriteriaCardiovascular risk factorsVariants of patientsThoracic malignanciesModified Delphi methodologyCardiac substructuresConsensus guidelinesRadiotherapyRisk factorsCardiac imagingComorbiditiesDose exposurePatientsSystematic reviewThoracic
2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patterns
2021
Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. Translational Lung Cancer Research 2021, 10: 3793-3806. PMID: 34733629, PMCID: PMC8512470, DOI: 10.21037/tlcr-21-632.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalObjective response rateSmall cell lung cancerOverall survivalThoracic radiotherapySubgroup analysisRT subgroupPlacebo-controlled phase 2 trialSmall cell lung cancer patientsCell lung cancer patientsPrevious thoracic radiotherapyPrior thoracic radiotherapyRelapsed SCLC patientsPhase 2 trialCell lung cancerLung cancer patientsOS benefitPFS benefitSCLC patientsPlacebo groupPlacebo armRT patientsCancer patientsControl rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply